Selection and expansion of natural killer cells for NK cell-based immunotherapy

• Published in: Cancer Immunology, Immunotherapy Vol. 65; no. 4; pp. 477 - 484
• Main Authors: Becker, Petra S. A., Suck, Garnet, Nowakowska, Paulina, Ullrich, Evelyn, Seifried, Erhard, Bader, Peter, Tonn, Torsten, Seidl, Christian
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-04-2016; Springer Nature B.V
• Subjects: Antigens; Blood & organ donations; Cancer; Cancer Research; Cell Culture Techniques - methods; Cell Proliferation; Cells, Cultured; Clinical trials; Cytotoxicity; Cytotoxicity, Immunologic - drug effects; Cytotoxicity, Immunologic - immunology; Expansion; Graft versus host disease; Humans; Immunoglobulins; Immunology; Immunotherapy; Immunotherapy, Adoptive - methods; Interleukin-2 - immunology; Interleukin-2 - pharmacology; Killer Cells, Natural - drug effects; Killer Cells, Natural - immunology; Killer Cells, Natural - transplantation; Leukemia; Leukocytes; Ligands; Medicine; Medicine & Public Health; Models, Immunological; Oncology; Receptors, KIR - immunology; Stem cell transplantation; Symposium-in-Writing Paper; Germany; Natural killer cells; Immunotherapy; Killer cell immunoglobulin-like receptor; Hematopoietic stem cell transplantation
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-016-1792-y

Natural killer (NK) cells have been used in several clinical trials as adaptive immunotherapy. The low numbers of these cells in peripheral blood mononuclear cells (PBMC) have resulted in various approaches to preferentially expand primary NK cells from PBMC. While some clinical trials have used the addition of interleukin 2 (IL-2) to co-stimulate the expansion of purified NK cells from allogeneic donors, recent studies have shown promising results in achieving in vitro expansion of NK cells to large numbers for adoptive immunotherapy. NK cell expansion requires multiple cell signals for survival, proliferation and activation. Thus, expansion strategies have been focused either to substitute these factors using autologous feeder cells or to use genetically modified allogeneic feeder cells. Recent developments in the clinical use of genetically modified NK cell lines with chimeric antigen receptors, the development of expansion protocols for the clinical use of NK cell from human embryonic stem cells and induced pluripotent stem cells are challenging improvements for NK cell-based immunotherapy. Transfer of several of these protocols to clinical-grade production of NK cells necessitates adaptation of good manufacturing practice conditions, and the development of freezing conditions to establish NK cell stocks will require some effort and, however, should enhance the therapeutic options of NK cells in clinical medicine.